scholarly journals Effects of Intraperitoneal and Intrathecal Morphine Analgesia on the Expression of μ-Opioid Receptors in Bone Cancer Pain Rats

Dose-Response ◽  
2019 ◽  
Vol 17 (4) ◽  
pp. 155932581988287 ◽  
Author(s):  
Wei Liu ◽  
Heqi Liu ◽  
Zongde Zhang ◽  
Jiapeng Huang
Keyword(s):  
Cancer Pain ◽  
Opioid Receptor ◽  
Intrathecal Morphine ◽  
Bone Cancer ◽  
Receptor Expression ◽  
Bone Cancer Pain ◽  
Control Group ◽  
Expression Levels ◽  
Significant Difference ◽  
Μ Opioid Receptor

Backgrounds: This study compared analgesic effects and μ-opioid receptor expression levels during long-term intraperitoneal and intrathecal treatment in a bone cancer pain rat. Methods: Twenty-four female Sprague-Dawley rats were injected Walker 256 tumor cells into the femur to create a bone cancer pain model. The control group was injected with saline intraperitoneally and intrathecally. The intraperitoneal group was injected with morphine intraperitoneally and saline intrathecally. The intrathecal group was injected saline intraperitoneally and morphine intrathecally. Changes in pain threshold, μ-opioid receptor expression levels in spinal cord, and tumor tissue were compared between 3 groups. Results: The intrathecal morphine group and the intraperitoneal group showed no difference in analgesia effects ( P > .05). Western blot and immunohistochemical staining of μ-opioid receptors demonstrated that its level in the intrathecal group was significantly lower than the intraperitoneal group ( P < .05) and without significant difference with the control group ( P > .05). The expression levels of μ-opioid receptor in the spinal cord tissue did not reveal a difference among these 3 groups ( P > .05). Conclusion: Intrathecal group and intraperitoneal group showed significant difference in μ-opioid receptor expressions although with no difference in analgesia effects. Long-term intrathecal morphine administration provided similar analgesia compared to systemic morphine.

scholarly journals Effect of the Norepinephrine Transporter (NET) Inhibition on μ-Opioid Receptor (MOR)-Induced Anti-nociception in a Bone Cancer Pain Model

2014 ◽  
Vol 125 (3) ◽  
pp. 264-273 ◽  
Author(s):  
Hiroko Ono ◽  
Atsushi Nakamura ◽  
Tomoe Kanbara ◽  
Kazuhisa Minami ◽  
Shunji Shinohara ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Opioid Receptor ◽  
Bone Cancer ◽  
Norepinephrine Transporter ◽  
Bone Cancer Pain ◽  
Pain Model ◽  
Μ Opioid Receptor

scholarly journals Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model

2012 ◽  
Vol 168 (2) ◽  
pp. 375-388 ◽  
Author(s):  
Atsushi Nakamura ◽  
Minoru Hasegawa ◽  
Kazuhisa Minami ◽  
Tomoe Kanbara ◽  
Takako Tomii ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Opioid Receptor ◽  
Bone Cancer ◽  
Brain Regions ◽  
Bone Cancer Pain ◽  
Pain Model ◽  
Differential Activation ◽  
Μ Opioid Receptor

scholarly journals Intrathecal Substance P-Saporin in the Dog

2013 ◽  
Vol 119 (5) ◽  
pp. 1178-1185 ◽  
Author(s):  
Dorothy Cimino Brown ◽  
Kimberly Agnello
Keyword(s):  
Substance P ◽  
Cancer Pain ◽  
Antinociceptive Effect ◽  
Intrathecal Injection ◽  
Bone Cancer ◽  
Standard Of Care ◽  
Bone Cancer Pain ◽  
Controlled Study ◽  
Control Group ◽  
Analgesic Therapy

Abstract Background: Substance P-saporin (SP-SAP), a chemical conjugate of substance P and a recombinant version of the ribosome-inactivating protein, saporin, when administered intrathecally, acts as a targeted neurotoxin producing selective destruction of superficial neurokinin-1 receptor–bearing cells in the spinal dorsal horn. The goal of this study was to provide proof-of-concept data that a single intrathecal injection of SP-SAP could safely provide effective pain relief in spontaneous bone cancer pain in companion (pet) dogs. Methods: In a single-blind, controlled study, 70 companion dogs with bone cancer pain were randomized to standard-of-care analgesic therapy alone (control, n = 35) or intrathecal SP-SAP (20–60 µg) in addition to standard-of-care analgesic therapy (n = 35). Activity, pain scores, and videography data were collected at baseline, 2 weeks postrandomization, and then monthly until death. Results: Although the efficacy results at the 2-week postrandomization point were equivocal, the outcomes evaluated beyond 2 weeks revealed a positive effect of SP-SAP on chronic pain management. Significantly, more dogs in the control group (74%) required unblinding and adjustment in analgesic protocol or euthanasia within 6 weeks of randomization than dogs that were treated with SP-SAP (24%; P &lt; 0.001); and overall, dogs in the control group required unblinding significantly sooner than dogs that had been treated with SP-SAP (P &lt; 0.01). Conclusion: Intrathecal administration of SP-SAP in dogs with bone cancer produces a time-dependent antinociceptive effect with no evidence of development of deafferentation pain syndrome which can be seen with neurolytic therapies.

scholarly journals Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine toleranceviaµ-opioid receptor

2015 ◽  
Vol 138 (8) ◽  
pp. 2013-2020 ◽  
Author(s):  
Zongming Jiang ◽  
Shaoyong Wu ◽  
Xiujuan Wu ◽  
Junfeng Zhong ◽  
Anqing Lv ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Opioid Receptor ◽  
Mammalian Target Of Rapamycin ◽  
Bone Cancer ◽  
Target Of Rapamycin ◽  
Bone Cancer Pain
Sign in / Sign up

Export Citation Format

Share Document